Phase i and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 167-175

  Lin, Chia Chi ^a,e   Beeram, Muralidhar ^a,b,f   Rowinsky, Eric K ^a,b,g   Takimoto, Chris H ^a,b,h   Ng, Chee M ^a,b,i   Geyer Jr , Charles E ^c,j   Denis, Louis J ^a,k   De Bono, Johann S ^a,n   Hao, Desiree ^a,o   Tolcher, Anthony W ^a,b,p   Rha, Sun Young ^a,l   Jolivet, Jacques ^d,m   Patnaik, Amita ^p  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Joe Arrington Cancer Center   (United States)

^d SHIRE   (United States)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f TEXAS ONCOLOGY   (United States)

^g ImClone Systems   (United States)

^h Ortho Biotech Oncology Research and Development   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j ALLEGHENY GENERAL HOSPITAL   (United States)

^k PFIZER INC   (United States)

^l Yonsei University College of Medicine   (South Korea)

^m INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

ⁿ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^o TOM BAKER CANCER CENTRE   (Canada)

^p South Texas Accelerated Research Therapeutics   (United States)

more..

Author keywords

Cisplatin; Pharmacokinetics; Phase I; Troxacitabine

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PROCHLORPERAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TROXACITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CREATININE CLEARANCE; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HALF LIFE TIME; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTOSINE; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349621823     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1020-y     Document Type: Article

References (22)

1. KL Grove X Guo SH Liu, et al. 1995 Anticancer activity of beta-l-dioxolane-cytidine, a novel nucleoside analogue with the unnatural l configuration Cancer Res 55 3008 3011 7606719 1:CAS:528:DyaK2MXmvVyitr0%3D
2. H Gourdeau ML Clarke F Ouellet, et al. 2001 Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines Cancer Res 61 7217 7224 11585758 1:CAS:528:DC%2BD3MXnsVeht7g%3D
3. P Krishnan Q Fu W Lam, et al. 2002 Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of l-nucleoside analog diphosphates by 3-phosphoglycerate kinase J Biol Chem 277 5453 5459 11741981 10.1074/jbc.M109025200 1:CAS:528:DC%2BD38XhsFCjtrs%3D (Pubitemid 34968594)
4. KM Chou M Kukhanova YC Cheng 2000 A novel action of human apurinic/apyrimidinic endonuclease: excision of l-configuration deoxyribonucleoside analogs from the 3' termini of DNA J Biol Chem 275 31009 31015 10906132 10.1074/jbc.M004082200 1:CAS:528:DC%2BD3cXntlCisrw%3D
5. M Kukhanova SH Liu D Mozzherin, et al. 1995 l- and d-enantiomers of 2', 3'-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications of the mechanism of toxicity J Biol Chem 270 23055 23059 7559445 10.1074/jbc.270.39.23055 1:CAS:528:DyaK2MXosFyjsLg%3D
6. FJ Giles JE Cortes SD Baker, et al. 2001 Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia J Clin Oncol 19 762 771 11157029 1:CAS:528:DC%2BD3MXhtlGrt7w%3D
7. JS de Bono J Stephenson Jr SD Baker, et al. 2002 Troxacitabine, an l-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies J Clin Oncol 20 96 109 11773159 10.1200/JCO.20.1.96 (Pubitemid 34032601)
8. K Belanger M Moore SD Baker, et al. 2002 Phase I and pharmacokinetic study of novel l-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days J Clin Oncol 20 2567 2574 12011137 10.1200/JCO.2002.12.047 1:CAS:528:DC%2BD38XksFaku7w%3D (Pubitemid 34525745)
9. CK Lee EK Rowinsky J Li, et al. 2006 Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue Clin Cancer Res 12 2158 2165 16609029 10.1158/1078-0432.CCR-05-2249 1:CAS:528:DC%2BD28XjtlChs78%3D
10. MA Moufarij DR Phillips C Cullinane 2003 Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines Mol Pharmacol 63 862 869 12644587 10.1124/mol.63.4.862 1:CAS:528:DC%2BD3sXisFeksLY%3D (Pubitemid 36368993)
11. CJ van Moorsel HM Pinedo G Veerman, et al. 1999 Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines Br J Cancer 80 981 990 10362105 10.1038/sj.bjc.6690452 1:CAS:528:DyaK1MXjvFSitb0%3D (Pubitemid 29233918)
12. M Crul RC van Waardenburg S Bocxe, et al. 2003 DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin Biochem Pharmacol 65 275 282 12504803 10.1016/S0006-2952(02)01508- 3 1:CAS:528:DC%2BD38Xpslamur0%3D (Pubitemid 36015830)
13. LY Yang L Li H Jiang Y Shen W Plunkett 2000 Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair Clin Cancer Res 6 773 781 10741696 1:CAS:528: DC%2BD3cXisVaqtrg%3D
14. D Perrier M Mayersohn 1982 Noncompartmental determination of the steady-state volume of distribution for any mode of administration J Pharm Sci 71 372 373 7069605 10.1002/jps.2600710332 1:STN:280:DyaL387mvF2msg%3D%3D (Pubitemid 12083746)
15. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine
16. SD Baker J Verweij EK Rowinsky, et al. 2002 Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 J Natl Cancer Inst 94 1883 1888 12488482 1:CAS:528:DC%2BD3sXlsFyisA%3D%3D
17. FA Shepherd R Burkes Y Cormier, et al. 1996 Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose J Clin Oncol 14 1656 1662 8622085 1:CAS:528:DyaK28XjtFKisbc%3D
18. FJ Giles HM Kantarjian JE Cortes, et al. 2003 Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia J Clin Oncol 21 1722 1727 12721247 10.1200/JCO.2003.11.016 1:CAS:528:DC%2BD2cXpsVWqsbY%3D (Pubitemid 46638583)
19. SF Dent A Arnold DJ Stewart, et al. 2005 Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer Lung 183 265 272 16211462 10.1007/s00408-004-2539-7 1:CAS:528:DC%2BD2MXhtVykurrL (Pubitemid 41428098)
20. R Lapointe R Letourneau W Steward, et al. 2005 Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors Ann Oncol 16 289 293 15668286 10.1093/annonc/mdi061 1:STN:280:DC%2BD2M%2FjvFyhsQ%3D%3D (Pubitemid 40309312)
21. A Jimeno WA Messersmith CK Lee, et al. 2008 Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies Ann Oncol 19 374 379 18245131 10.1093/annonc/mdm572 1:STN:280:DC%2BD1c%2FoslCqsw%3D%3D (Pubitemid 351201723)
22. GJ Roboz FJ Giles EK Ritchie, et al. 2007 Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia J Clin Oncol 25 10 15 17146106 10.1200/JCO.2006.06.6209 1:CAS:528:DC%2BD2sXht1ejsrY%3D (Pubitemid 350003045)